COBO Technologies is a fast-growing start-up company based in Copenhagen, Denmark, that specializes in products and services for Quality Control (QC) of CRISPR modified cells and animals. The team behind COBO comes from senior positions in science, commercial and operation, with more than 10 years experience in the CRISPR field. Within the last 5 years, the CRISPR field has developed from more than 100 publications per year to now more than 5,000 publications per year and the number of ongoing clinical trials using a CRISPR tool is now more than 60. In 2020 two CRISPR scientists received the Nobel Prize in Chemistry for their CRISPR inventions, proving that this is a fast-growing field which is now moving from research to clinics. In consequence, there is a need for platforms that can support efficient QC of CRISPR cells. In more general terms, there is a need to understand what are the safety effects of altering DNA with CRISPR — hitting the right target gene, checking how efficient the DNA change is, and investigating other DNA changes that were not expected. Most of the solutions offered today for cell/DNA analysis are not developed specifically for CRISPR applications. They are expensive, lack sensitivity and are time-consuming and they are done by service companies with no/or little knowledge about CRISPR. Based on our experience from the CRISPR field and feedback from our network in the EU and US, we have developed proprietary platforms that can support the current needs for QC of CRISPR cells. Including both proven reagents for sample preparation, cell analysis and bioinformatics, this is the first full-package solution developed specifically for CRISPR clients. In addition, it combines low cost, high sensitivity and fast delivery time - 3 factors essential for our clients. We have used the past year to build up a scalable operation in Denmark in a low-risk setup and are now ready to speed up the growth first in the EU and then later 2021 in the US. In addition, we will also start the initial preparation of our first development project for a clinical application at the end of 2021. Since the start 2018, COBO has supported more than 15 clients in both EU and US, including leading pharma companies and some of the leading universities in the world. We have developed unique platforms, we have clients every week, we have the network and we have the skills to be a major player in the global CRISPR field and be part of the development of future CRISPR Medicine to treat genetic diseases. As of today, COBO Technologies is backed by an angel investor.

For 4 years we have been developing an innovative visual data collection solution that transforms operations and analytics within any organisation that carries out inspections. Our customers believe that what we do is unique and we love the fact that every one of our customers has renewed their Captego subscription every year. We are a Danish company that’s growing quickly throughout Europe. We operate in the UK, have a remote team spread throughout most of Europe and it won’t be long before we have customers in new European markets. We use English for all of our internal communication. We don’t mind where in Europe you’re based or what time you get out of bed, we only care that you want Captego to be a success as much as our customers do.

Bankly har siden 2018 etableret sig som en markant fintech-spiller på det danske marked, og vi startede med det formål at skabe transparens på et meget komplekst marked og hjælpe danskerne med at spare penge. Det gør vi ved at indsamle personlige lånetilbud til vores brugere, som dermed kan finde det bedste og billigste tilbud på markedet hurtigt og nemt.

World's 1st AI platform that uses graph technology that applies for Jobs and monitors the market 24/7. Welcome to the new age. Swiftly aims to provide equal opportunities to 100% of the community instead of placing just the top talent removing bias and promoting inclusion along the way. Therefore, we aim at uplifting the community by bringing a revolutionary product to the market that bridges the very knowledge gap that exists between learning and recruiting. In this journey, Swiftly has already been recognized by companies like Google for startups, Wellstreet, and Coompanion. Some of the top companies are already participating in the beta. If you’re as passionate as us, follow us on our journey in shaping the future of recruitment!

Squire is a service marketplace that facilitates the connection between freelancers providing their services and customers in need of service help. If you want to work on Squire, you can experience true freedom and flexibility as you can choose when you work, what services you provide, and how much you charge. For customers looking for service help, Squire offers a variety of categories to choose from. Here they can find freelancers and businesses ready to offer their services. We have experienced that many people around us have lost their jobs. We want to build a solution to this, providing people who have lost their income a means to earn a living. Efficient access to services is something we believe the danish economy lacks, by facilitating new demand and supply for service jobs, we hope to stimulate the economy by creating a platform that encourages spending and income generation opportunities during a time of suppressed economic growth.

Jamii.one is bridging Sub-Saharan Africa’s vast insurance gap by digitising community-based group (CBG) data, making insurance affordable for Ethiopians and sustainable for insurers. Their offline-first app, offered in local languages, allows CBGs to transition from paper to digital, enhancing financial transparency and creditworthiness. Once digitised, groups unlock tailored insurance products. This solution simplifies bookkeeping for CBGs while providing insurers a low-cost, reduced-risk entry to previously unreachable segments. With 650,000 users, and 70,000 purchasing life insurance, Jamii.one epitomises how tech can foster financial resilience. Their platform, rooted in tech innovation and community trust, ensures accessible, relevant financial services for underserved communities.

We use robots to automate and democratize access to healthcare! The groundbreaking robot, Careebo, has been designed and developed by a team of robotics researchers at the Maersk Mc-Kinney Moller Institute at the University of Southern Denmark (SDU) in Odense, a city home to one of the world’s leading robotics clusters. The robot was developed as a response to the COVID-19 pandemic and the issues we suddenly faced as a global society. Clearly, we were not ready - we want to change that! The pandemic led to cross-infection between citizens and healthcare workers, low qualtiy samples due to inter-personal variability, and unequal access to basic healthcare such a swab sample. At Lifeline Robotics, we aim to enhance our pandemic preparedness and global health securty by utilizing automation and robotics to create a system which enables ongoing and implemented monitoring of what moves around in our societies. We envision, that this system can be implemented at strategic locations, so citizens can easily engage before travelling, attending big events or visiting vulnerable family.

Nordic Health Lab bygger bro mellem private virksomheder og det offentlige sundhedssystem og hjælper med at udvikle og teste innovative sundhedsløsninger. De sidste måneder har i høj grad understreget, at verden står overfor stor sundhedsmæssige udfordringer - men heldigvis er der masser af kloge, skæve, underfundige og innovative idéer, som med den rette støtte kan realiseres og komme os alle sammen til gavn. Vi skaber løsningerne gennem co-creation med startups, multinationale virksomheder, sundhedsprofessionelle, borgere/patienter og andre relevante aktører.

Source is a talent intelligence platform that helps companies move quicker, reduce hiring costs, and acquire top technical talent. Sourcing talent faces three major problems, which we will solve: Problem #1: Every company we worked for had difficulty finding the right software developers. With the plethora of technical skills (1,000+) on the market and uncertainty in seniority, finding the missing piece to achieving the dream team was quite cumbersome. Problem #2: The time to source candidates for one role is between 13 and 20 hours a week. In other words, one-third to a half of a week's work. This leads to inefficiency, high costs, and worst of all incredibly-high burnout rates in the recruiting industry. Problem #3: The internal cost-per-hire is roughly around $4,700, and outsourced costs can reach sums as high as $50,000. Again, per hire. Let that sink in... How do we do it: By giving talent acquisition professionals a powerful talent search engine, they are able to perform smarter, cheaper, and faster than ever before. Instead of being powered by LinkedIn or Google, Sourcemoon is powered by data found on GitHub—the most popular platform among software developers. We use GitHub API, scraping, and parsing algorithms to collect and make sense of data from GitHub (other platforms coming in the future). The market is large and growing: The global talent acquisition & staffing market is valued at $141B, growing 5% YoY, and the global recruitment software market is valued at $8B.

Barona has launched the most cost efficient and full service IT-recruitment partnership in DK providing international IT candidates through search, hire, relocation, housing, and settlement. When recruiting is not enough to solve the talent gap we design elevate programs in order to build new tech competences and secure future growth for our customers. Local talent recruitment and staffing is also part of our core business and close to our hearts, thus we can fill any short or long term position within IT through recruitment marketing, search and headhunting.

Tomorrow (tomorrow.today) er en ny, non-profit organisation, der er sat i verden for at skabe bæredygtige adfærdsforandringer. Vi gik i luften for første gang i 2021 med tre store events på samme tid: En stor festival i Valbyparken (Tomorrow Festival), en international “handletank” med eksperter og aktivister fra hele verden (Imagine Tomorrow) og et topmøde for ledere og virksomheder (Tomorrow Summit). Alle tre platforme handler om bæredygtige handlinger.

We're advancing micro-encapsulation technology solutions. Effective delivery of bioactives (including probiotics) via micro-encapsulation is still an industry-wide issue. The technology is not yet mature enough to provide adequate and prolonged stability or efficiently deliver to the target site in the body. We at Mello are changing the game for bioactive delivery. We're working closely with Danish Technological Institute to develop the first water-free process, necessary to generate a lipid-based TrueCoreTM particle at micro size. We're building a delivery platform for different bioactives. We aim to be THE market leader in delivery solutions for sensitive and unstable 'actives'.

Hos Npvision Group har vi specialiseret os i køb og salg af brugt IT udstyr. Fremgangsmåden er følgende: » IT udstyret bliver afhentet af uddannet personale i sikre lastbiler. » Udpakning og optælling af jeres IT udstyr » Datasletning efter tidens højeste standarder » Til sidst afregner vi for det brugte IT udstyr

LABWORK is a SaaS company founded in 2017 with the purpose of optimizing the way dentists and dental labs communicate. Our platform connects dentist and dental labs and takes ordering dental lab work from carbon copy paper into the digital age. With an innovative and simple approach we have integrated the entire workflow from order to delivery into a single online solution and made communication with patient sensitive information safe. We have 100+ dental clinics subscribed and 30+ dental labs in Denmark alone. Currently we're looking for a co-founder with it skills to help develop the platform further and expand to other countries.

TAG Sensors utvikler og produserer kombinerte NFC-/RFID-tags for kontinuerlig overvåkning av kjølekjede for varer fra produsent til sluttbruker. Gjennom vår løsning får kundene kontroll på at temperaturfølsomme varer som fisk, frossen mat og farmasiprodukter har vært innenfor temperaturgrensene fra produksjon til forbruk.